NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

But some Dividend Kings are better than others. Here's my favorite Dividend King to buy in November.

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological ...

AbbVie posts strong Q3 results with $7.89B immunology sales, rising Elahere revenue, and Rinvoq Phase 3 success. Learn why ABBV stock is a strong buy.

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some ...

The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...

Drugmaker AbbVie sued the state in June because of Senate Bill 71, which forbade drug companies from limiting how many ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers. The Food and Drug ...

AbbVie’s ($ABBV) shares weakened on Friday, despite the American drugmaker’s third-quarter fiscal year 2025 earnings surpassing Wall Street’s ...

Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes ...

AbbVie's Q3 2025 earnings are in. Skyrizi is on fire, neuroscience is booming, but Botox is a bust. Get the summary.

The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to ...